Phage Therapy Market Analysis Europe, North America, Asia, Rest of World (ROW) - US, Canada, Poland, UK, China - Size and Forecast 2024-2028

Phage Therapy Market 2024-2028

The global phage therapy market size is estimated to grow by USD 51 million, at a CAGR of 17.41% between 2023 and 2028. 

Phage therapy encompasses the treatment of a wide range of bacterial diseases and disorders in humans, including acne and eczema, internal bacterial infections like pneumonia, wound infections, and epidemics like diphtheria or cholera. It is also used in the treatment of UTIs. An estimated 150 million people worldwide get urinary tract infections (UTIs) annually. Furthermore, antibiotic-resistant E. coli has been recognized by the World Health Organisation (WHO) and the US Centres for Disease Control and Prevention (CDC) as a severe public health problem that requires the development of new treatments. Locus Biosciences offers LBP-EC01, which is a precision medicine designed to target E. coli infections. It is a cocktail of bacteriophages produced to effectively remove E. coli bacteria in patients with UTIs. Thus, increasing the application of phage therapy for human health will drive the growth of the market during the forecast period. 

Technavio has segmented the market into Product, Application and Geography

• The product  segment includes escherichia coli, staphylococcus aureus, salmonella, and others
• The application segment includes animal health, food industry, and others
• The geography segment includes key regions such as Europe, North America, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Product, Application and Geography Analysis

Product Analysis 

Escherichia coli

The market share growth by the escherichia coli segment will be significant during the forecast period. Bacteria known as Escherichia coli, or simply E. coli, are found in food, the environment, and the intestines of both humans and animals. The bacteria known as E. Coli are many and varied. While the majority of E. Coli strains are not harmful, some can cause illness.

Get a glance at the market contribution of various segments Download PDF Sample

The escherichia coli was the largest and was valued at USD 9.62 million in 2018. While some strains of E. Coli can cause ailments such as pneumonia, respiratory disorders, and urinary tract infections, other strains can induce diarrhea. Phage therapy has been gaining prominence for the treatment of Escherichia coli. Thus, various key vendors have been involved in clinical trial phage therapy for Escherichia coli. Enrollment in a Phase I/IIa clinical trial for Intralytix EcoActive phage therapy, which targets adherent-invasive Escherichia coli (AIEC) in Crohn disease patients, began in 2019 at the Icahn School of Medicine at the Mount Sinai Hospital in New York. Thus, such clinical trials will drive the growth of the segment and the market during the forecast period.

Application Analysis 

Animal health

The overuse of antibiotics has caused MDR microorganisms to proliferate. These infections, which present health and economic challenges, have emerged mostly due to the conventional abuse of antibiotics in the animal feed business. In addition, antibiotics have also lately undergone an increase in treating companion animal infections, boosting the rise of MDR bacteria in pets, which can reach people. Phages have been proposed as a replacement for antibiotics for the treatment of livestock and companion animal illnesses due to their various advantages as adaptative medications, such as their ability to evolve to grow at the site of infections and their high specificity. CJ CheilJedang offers a phage cocktail of feed additives. It has strong antimicrobial activity against Salmonella, C.perfringens, and Escherichia coli and thus decreases bacterial disease in farms. It also prevents Salmonella contamination in eggs and chickens to supply safe livestock products. Thus, such product offerings by the vendors will drive the growth of the segment and the market during the forecast period.

Food industry

The food industry uses phages in three areas: biosanitization, biopreservation, and primary production. Phage-producing enzymes, or phages themselves, are primarily employed in biosanitization to stop biofilms from growing on the surfaces of manufacturing facility equipment. Phages are used in biopreservation to fight harmful bacteria that deteriorate food, therefore extending the shelf life of items. Phage cocktails are a green technology that effectively combats food-borne pathogenic and spoilage bacteria. The following are some more benefits of applying phages in the food chain: Because of their high level of specificity, bacteriophages often only infect a single species or kind of bacteria. Thus, the normal commensal microbiota in the gastrointestinal system of humans and animals is not eradicated. The use of bacteriophages on eukaryotic cells has not been shown to have any harmful or toxic effects. Phages do not change the properties of food products. Thus, such applications of phage therapy will drive the growth of the segment and the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

Europe is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Germany and the UK are the leading contributors to the market in Europe. Factors such as the strong presence of quality healthcare providers and patient care services, well-developed healthcare infrastructure, increasing investments in the healthcare sector, and growing support from governments for research activities are driving the market growth during the forecast period. The region has witnessed high Tuberculosis ( TB) detection rates in 2023. This leads to the high adoption of phage therapy for TB types, such as multidrug-resistant TB or extensively drug-resistant TB. This leads to the high adoption of phage therapy for TB types, such as multidrug-resistant TB or extensively drug-resistant TB. Also, the presence of leading vendors such as Micreos, APS Biocontrol, and Nexabiome will positively impact the market. 

In addition, the region is also home to several associations, such as the Norwegian Directorate of Health and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). These committees aim to provide technical aspects of bacterial diseases, quality assurance, and educational workshops. All these factors are expected to drive the growth of the market in the region during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including: 

Adaptive Phage Therapeutics - The company offers phage therapy such as PT phage bank therapy which can be used in laboratories.

• APS Biocontrol Ltd.
• Armata Pharmaceuticals Inc.
• Astellas Pharma Inc.
• BiomX Inc.
• CJ CheilJedang Corp.
• Cytophage Technologies Inc.
• Eliava Biopreparation LLC
• Intralytix Inc.
• iNtRON Biotechnology Inc.
• JSC NPO Microgen
• Locus Biosciences Inc.
• Micreos
• Micromir
• Nexabiome
• Proteon Pharmaceuticals S.A.
• Taconic Biosciences Inc.
• TechnoPhage
• ZeptoMetrix LLC
• Vitalis Wellness LLP

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, market trends and analysis, and challenges. 

Key Drivers

The increasing application of phage therapy for animal health is notably driving market development. Phage therapy is considered to be a possible treatment for disorders that pathogenic bacteria cause in animals. Cytophage Technologies is creating bacteriophages that will minimize and ultimately replace the usage of antibiotics for sickness prevention and growth augmentation in animals. Overusing antibiotics in food production has developed antibiotic-resistant microorganisms. Therefore, to avoid infections and promote animal growth, the Canadian government has modified legislation related to antibiotics.

However, like other phages, those created for swine applications will be a highly efficient, safe for the environment, and reasonably priced substitute for antibiotics that swine farms can incorporate into their herd health plans. Thus, increasing the application of phage therapy for animal health will drive market growth and trends during the forecast period.

Significant  Trends

Increasing clinical trials for phage therapy is an emerging trend shaping market growth. In the last five years, phage therapy has undergone a revitalization due to the growing problem of AMR, with few new antibiotics in the pipeline and a growing number of high-profile reports where phage therapy was used to successfully treat life-threatening multidrug-resistant bacterial infections. Limitations of anti-biotics that had thwarted the pharmaceutical industry are now being overcome with advances in high-throughput sequencing, metagenomics, genetic engineering, and synthetic biology. 

Similarly, in November 2023, top-line results from the Phase 2 part of an ongoing Phase 1b/2a clinical trial show that BX004, an inhaled phage therapy being developed for chronic Pseudomonas aeruginosa lung infections, led to clinically meaningful improvements in lung function for cystic fibrosis (CF) patients with pre-existing lung impairments. The treatment creator, BiomX, now intends to move BX004 forward to a pivotal Phase 2b/3 trial, subject to funding and regulatory input. Thus, such factors drive the market growth during the forecast period. 

Major  Challenges

High regulatory control for phage therapy is a significant challenge hindering market growth. Phages are regulated by pharmaceutical laws since regulatory bodies have categorized them as biological materials. Both the US and EU regulatory frameworks establish that pharmaceuticals prepared industrially or made using a method incorporating an industrial process must have marketing authorization. As a result, phage product marketing necessitates evidence of safety and effectiveness in addition to manufacturing quality by GMP. For hospitals or non-profit phage therapy centers, GMP compliance is a major cost barrier that must be 

Moreover, for phages, recommended criteria include the absence of prophages and antibiotic resistance in the bacteria used to produce the phage(s), the lytic (non-temperate) and specific activity of individual phages on the target bacteria, the control for impurities (e.g., endotoxins, residual reagents) in phage preparations, and the test for potency and purity of the phages. This regulation is inadequate for patient-specific, customized phage cocktails whose composition is variable and not intended for large-scale distribution. Thus, high regulatory control for phage therapy will negatively impact the market growth during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market research and growth report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market analysis and report also include key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Product Outlook
  • Escherichia coli
  • Staphylococcus aureus
  • Salmonella
  • Others

• Application Outlook
  • Animal health
  • Food industry
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Phage Therapy Market Scope
Report Coverage	Details
Page number	156
Base year	2023
Historic period	2018-202
Market forecasting period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 17.41%
Market Growth 2024-2028	USD 51 million
Market structure	Fragmented
YoY growth 2023-2024(%)	14.43
Regional analysis	Europe, North America, Asia, and Rest of World (ROW)
Performing market contribution	Europe at 34%
Key countries	US, Canada, Poland, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Adaptive Phage Therapeutics, APS Biocontrol Ltd., Armata Pharmaceuticals Inc., Astellas Pharma Inc., BiomX Inc., CJ CheilJedang Corp., Cytophage Technologies Inc., Eliava Biopreparation LLC, Intralytix Inc., iNtRON Biotechnology Inc., JSC NPO Microgen, Locus Biosciences Inc., Micreos, Micromir, Nexabiome, Proteon Pharmaceuticals S.A., Taconic Biosciences Inc., TechnoPhage, ZeptoMetrix LLC, and Vitalis Wellness LLP
Market dynamics	Parent market growth analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Phage Therapy Market  Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size of the size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across Europe, North America, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch